A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
NCT ID: NCT03251118
Last Updated: 2025-11-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
15000 participants
OBSERVATIONAL
2017-07-24
2026-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
NCT05230173
Improving the Quality of Care for Adults With Inflammatory Bowel Disease
NCT02791854
Advanced Therapy Registry of IBD Patients
NCT04998084
Interactions Between Immune Cells of Intestinal Mucosa or Peripheral Blood With the Extracellular Matrix in Inflammatory Bowel Disease (IBD)
NCT00915044
Research and Follow-up of the Determinants of the Progression and Complications of Inflammatory Bowel Diseases Treated or Not With Immunosuppressants.
NCT07172945
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Have plans for future visits at the site for continued management of IBD.
Exclusion Criteria
2. Being enrolled in any interventional study or trial for IBD treatment. Note: Patient may be enrolled in other registries or studies where IBD treatment outcomes are observed and/or reported (such as center-based registries).
3. Prior total abdominal colectomy for UC or IBDU.
2 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Target PharmaSolutions, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Om Research
Lancaster, California, United States
FACEY Medical Foundation
Mission Hills, California, United States
University of California - Davis
Sacramento, California, United States
Stanford University
Stanford, California, United States
University of Colorado Denver
Aurora, Colorado, United States
Gastro Florida
Clearwater, Florida, United States
University of Florida Health Jacksonville-Gastroenterology
Jacksonville, Florida, United States
Advanced Gastroenterology Associates, LLC
Palm Harbor, Florida, United States
Atlanta Gastro
Atlanta, Georgia, United States
The University of Chicago Medical Center
Chicago, Illinois, United States
Indianapolis Gastroenterology Research Foundation
Indianapolis, Indiana, United States
University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
Gastroenterology Associates
Baton Rouge, Louisiana, United States
Louisiana Research Center, LLC
Shreveport, Louisiana, United States
University of Michigan Medical Center
Ann Arbor, Michigan, United States
University of Minnesota
Minneapolis, Minnesota, United States
Saint Louis University
St Louis, Missouri, United States
University of Nebraska Medical Center
Omaha, Nebraska, United States
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States
Rutgers, Robert Wood Johnson Medical School
New Brunswick, New Jersey, United States
NYU Langone Health
New York, New York, United States
Mount Sinai, Icahn School of Medicine
New York, New York, United States
Premier Medical Group of the Hudson Valley
Poughkeepsie, New York, United States
The Children's Hospital at Montefiore
The Bronx, New York, United States
Cary Gastroenterology Associates
Cary, North Carolina, United States
University of North Carolina
Chapel Hill, North Carolina, United States
Carolinas Healthcare System-Center for Digestive Health
Charlotte, North Carolina, United States
Digestive Health Specialists, PA
Winston-Salem, North Carolina, United States
Cleveland Clinic/DIgestive Disease and Surgery Institute
Cleveland, Ohio, United States
The Ohio State University Wexner Medical Center
Columbus, Ohio, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
UT Southwestern
Dallas, Texas, United States
Baylor College of Medicine
Houston, Texas, United States
Swedish Medical Center
Seattle, Washington, United States
MultiCare Institute for Research and Innovation
Tacoma, Washington, United States
University of Wisconsin Hospital & Clinics
Madison, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TARGET-IBD
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.